1. Michael S. Weiss - Executive Chairman and Chief Executive Officer: Mr. Weiss has over 20 years of experience in the biotechnology and pharmaceutical industries. Before joining TG Therapeutics, he co-founded several biopharmaceutical companies, including Medarex, Inc., a biopharmaceutical company specializing in antibody-based therapeutics. Mr. Weiss holds a B.A. from Columbia University and a J.D. from the New York University School of Law.
2. Sean A. Power - Chief Financial Officer: Mr. Power has more than 20 years of experience in finance, accounting, and operations. Prior to joining TG Therapeutics, he served as the Senior Vice President and Chief Financial Officer of Medicines Company. He holds a B.S. in Accounting from Babson College and an M.B.A. from the F.W. Olin Graduate School of Business at Babson College.
3. Michael S. Weiss - Executive Chairman and Chief Executive Officer: Mr. Weiss has over 20 years of experience in the biotechnology and pharmaceutical industries. Before joining TG Therapeutics, he co-founded several biopharmaceutical companies, including Medarex, Inc., a biopharmaceutical company specializing in antibody-based therapeutics. Mr. Weiss holds a B.A. from Columbia University and a J.D. from the New York University School of Law.
4. Adam Waldman - Chief Commercial Officer and Corporate Development: Mr. Waldman has over 25 years of experience in the biopharmaceutical industry, including leadership positions in corporate development and commercial operations. Before joining TG Therapeutics, he served as Vice President, Head of Business Development at Intellia Therapeutics.
5. Michael G. Martino - Independent Director: Mr. Martino has been a member of the Board of Directors since 2011. He is also a member of the Board of Directors of Oyster Point Pharma, Inc., a biotechnology company, and Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company. Mr. Martino was a partner at Debevoise & Plimpton LLP, where he focused on mergers and acquisitions and securities law.
6. Laurence N. Charlier - Independent Director: Mr. Charlier has been a member of the Board of Directors since 2017. He is also a member of the Board of Directors of Peloton Therapeutics and Aimmune Therapeutics. Mr. Charlier was previously the President and Chief Executive Officer of Omthera Pharmaceuticals, Inc.
7. Richard A. Levy - Independent Director: Mr. Levy has been a member of the Board of Directors since 2011. He is also a member of the Board of Directors of Xoma Corporation and Zosano Pharma Corporation. Mr. Levy previously served as the President and Chief Executive Officer of Scios, Inc.
Tg Therapeutics Inc currently has 399 employees.
News about Tg Therapeutics Inc Key Personnel |
Investigation Reveals TG Therapeutics Positive Net Revenue in Fourth Quarter and Full Year 2023 Despite Previous Losses
TG Therapeutics, a biopharmaceutical company specializing in the development of innovative treatments, has announced preliminary net revenue figures for the fourth quarter and full year 2023. The company reported net product revenue of approximately $40 million for the fourth quarter and $89 million for the full year. These figures come as a surprise, considering TG Therapeutics had recorded a cumulative net loss of $-26 million in the 12 months leading up to the third quarter of 2023.
The revelation of TG Therapeutics positive net revenue raises questions about the company s fina...
|
